

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

**PCT**WORLD INTELLECTUAL PROPERTY  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9607356A1

(51) International Patent Classification<sup>6</sup>:

A61B 17/00

A1

(11) International Publication Number:

WO 96/07356

(43) International Publication Date:

14 March 1996 (14.03.96)

(21) International Application Number: PCT/US95/11332

(22) International Filing Date: 6 September 1995 (06.09.95)

(30) Priority Data:

08/303,336

6 September 1994 (06.09.94)

US

08/481,712

7 June 1995 (07.06.95)

US

(71) Applicant: FUSION MEDICAL TECHNOLOGIES, INC.  
[US/US]; 1615 Plymouth Street, Mountain View, CA  
94043 (US).(72) Inventors: SAWYER, Philip, N.; 7600 Ridge Boulevard,  
Brooklyn, NY 11209 (US). SAWYER, Philip, M.; Apart-  
ment N-107, 350 Sharon Park Drive, Menlo Park, CA 94025  
(US). REICH, Cary, J.; 26502 Dapple Grey Drive, Laguna  
Hills, CA 92653 (US).(74) Agents: HESLIN, James, M. et al.; Townsend and Townsend  
Khourie and Crew, Steuart Street Tower, 20th floor, One  
Market Plaza, San Francisco, CA 94105 (US).(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH,  
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE,  
KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT,  
BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD,  
SZ, UG).


Published

With international search report.

(54) Title: METHODS AND ARTICLES FOR STAPLE LINE REINFORCEMENT

(57) Abstract

Wounds and tissues are sealed by first closing the wound using conventional fasteners and thereafter applying energy (14) to a fusible material placed over the wound region to seal perforations which may be present. The fusible material may be applied as a solid strip of collagent (10) to an underlying tissue, followed by application of radio frequency (14).



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## METHODS AND ARTICLES FOR STAPLE LINE REINFORCEMENT

### BACKGROUND OF THE INVENTION

The present invention is a continuation-in-part of Application Serial No. 08/303,336, filed on September 9, 1994, the full disclosure of which is incorporated herein by reference.

#### 1. Field of the Invention

The present invention relates generally to devices, articles, and methods for effecting and enhancing wound closure in tissue. More particularly, the present invention relates to the use of a fusible material together with fasteners for closing wounds, wherein energy is applied to the fusible material to seal the closure.

Chronic obstructive pulmonary diseases, such as emphysema and small airway diseases, affect from five to ten million people in the United States alone. In about ten percent of such cases, chronic alveolar inflammation is so severe that large portions of the lung are destroyed, resulting in greatly reduced oxygen exchange and significant breathing difficulties. Such cases can result in partial or complete disability, and in the worst cases death.

One procedure for treating advanced chronic obstructive pulmonary disease, referred to as a bullectomy or lung tailoring, involves the surgical excision of diseased lung tissue and suturing to close the lung along the excision line. Surgical resection of lung tissue is also performed for volume reduction, blebectomies, segmentectomies, lobectomies, wedge resections, bronchial resections, pneumonectomies, and pneumoreductions. Unfortunately, lung tissue is extremely fragile (particularly when weakened by diseases such as emphysema) and does not hold sutures well. The needle holes resulting from suturing can result in lung perforations which

leak large amounts of air. Such post-operative air leaks often require long hospital stays and result in a high morbidity rate for the procedures. For these reasons, bullectomies where the lung is closed by suturing are seldom performed at present.

The prognosis for bullectomy procedures has been significantly improved by the introduction of modern surgical stapling techniques. Multiple row linear staplers have been used to both cut and close diseased lung tissue in both wedge resection and lobectomy procedures. Further improvement in such staple bullectomy procedures has been reported with the use of bovine pericardial strips to buttress and reinforce the staple line used to close the lung along the resection edge.

Although a significant improvement over prior procedures, the use of pericardium-reinforced stapling techniques during lung resection procedures is still problematic. The staple holes in the pericardial strips can still present small lung perforations, particularly when the strip is under pressure. Even very small perforations can result in air leakage as high as 2-5 liters/min. Moreover, the pericardial strips are not uniformly secured to the underlying lung tissue, and the terminal and side edges of the strip can separate from and/or tear the adjoining tissue, further contributing to air leakage. In particular, since the pericardial strips are attached to the underlying tissue only by the staples, air can leak from the staple perforations or elsewhere outward past the edges of the strip, i.e., pericardial strips do not seal the tissue closure in any significant way. Additionally, the use of bovine pericardial strips does not appear to promote healing of the underlying lung tissue, and particularly does not appear to promote fibroblast ingrowth to seal lung perforations which may be present after the procedure. Finally, present procedures do not provide for sealing or patching diseased areas of the lung other than by excising the diseased tissue and sealing along the excision line with staples with or without a pericardium patch. It would thus be desirable to provide procedures where

diseased lung tissue could be sealed to prevent air leakage without the need to excise tissue.

## 2. Description of the Background Art

5           The use of bovine pericardial strips to reinforce lung staple lines in performing bullectomies for treating emphysema is described in Cooper (1994) *Ann. Thorac. Surg.* 57:1038-1039. Bovine pericardial strips of the type utilized for staple line reinforcement are commercially available from  
10   Bio-Vascular, Inc., St. Paul, Minnesota, under the trade name Peri-Strips™. U.S. Patent No. 5,156,613, PCT Application WO 92/14513, and copending Application Serial No. 08/231,998, assigned to the assignee of the present invention, describe a method for joining or reconstructing tissue by applying energy  
15   to a tissue site in the presence of a collagen filler material. Copending Application Serial No. 08/370,552, describes the use of an inert gas beam energy source for fusing collagen and other materials to tissue for joining or reconstructing the tissue. U.S. Patent No. 5,071,417,  
20   describes the application of laser energy to biological materials to seal anastomoses. U.S. Patent No. 5,209,776, describes protein materials which may be activated with energy and bonded to tissue. PCT Application WO 93/01758 describes an argon beam coagulator for treating tissue.

## SUMMARY OF THE INVENTION

25           The present invention provides improved methods and devices for closing wounds in tissue using fasteners, such as staples, pins, hooks, sutures, and the like. The fasteners  
30   are applied to tissue in a conventional manner to close the wound, and energy is applied thereafter to a material disposed in a region over an adjacent wound which (upon application of the energy) fuses to the tissue to enhance the wound closure and seal perforations which may be present in the region due  
35   to fastener placement or other causes.

          The fusible material is a biologic or biocompatible synthetic substance which will bond to underlying tissue upon application of energy from a suitable source, as described in

more detail hereinafter. Preferred is the use of biological materials, such as proteins and protein-containing mixtures, which will bond to tissue proteins (e.g. covalently, non-covalently, physically, and combinations thereof) upon  
5 application of suitable activating energy. Exemplary biological materials include collagen, gelatin, elastin, fibrinogen, fibrin, albumin, and composites and mixtures thereof.

The fusible material may be applied to the wound  
10 region as a solid phase or as a non-solid dispersible phase. By "solid phase," it is meant that the fusible material is formed as a sheet, layer, film, strip, patch, mesh, or the like, over the wound region. By "non-solid dispersible  
15 phase," it is meant that the fusible material is in the form of a liquid, gel, powder, or combinations thereof, which may be spread, sprayed, painted, or otherwise dispersed over the wound region. Regardless of its initial state, the fusible material will be in the form of a solid or gel layer after  
20 energy has been applied according to the method of the present invention. That is, solid sheets, layers, films, strips, patches, and the like, will remain as a solid (although the dimensions may alter slightly as the material is softened and fused to the underlying tissue) while meshes and non-solids  
will be converted into solid or gel layers.

25 The fusible material may be applied before, during, or after placement of the fasteners, and is preferably applied together with the fasteners as a backing or reinforcement layer, where the fusible material is initially held in place by the fasteners and subsequently fused to the underlying  
30 tissue upon the application of energy. Such procedures are particularly advantageous since they require only two steps, i.e., the simultaneous placement of fastener and fusible material followed by the application of energy to fuse the material to tissue and enhance the tissue closure by sealing  
35 any perforations which may have resulted from the prior placement of the fasteners (as described above).

Optionally, the solid phase forms of the fusible material, such as sheets, layers, films, strips, and patches,



may be reinforced with non-fusible materials to increase their strength and enhance their use as backings during the initial placement of the fasteners, particularly staples. Usually, the non-fusible materials will also be non-bioabsorbable so that the reinforcement material can remain in place to support the staples or other fasteners indefinitely. Exemplary reinforcement materials include meshes or braids composed of polymeric materials.

The methods of the present invention can rely on the application of energy from a wide variety of sources, including radiofrequency (RF) energy, laser energy, ultraviolet energy, ultrasonic energy, and the like. Preferred is the use of RF energy which can be provided by conventional electrosurgical power supplies operating at frequencies in the range from 200 kHz to 1.2. MHz. Particularly preferred is the use of RF energy applicators which provide a uniform, dispersed energy flux over a defined area, such as inert gas beam RF energy sources, more particularly argon beam RF energy sources. Standard electrocautery devices could also find use.

In the exemplary embodiment, the methods and devices of the present invention are used to enhance sealing of lung tissue in lung resection procedures where lung tissue has been removed along an excision line. Typically, the lung tissue is excised and closed using a conventional multiple row, linear stapler. The fusible material is applied as a backing or reinforcement layer with the staples, preferably being placed on or over the stapler head and/or anvil prior to stapling. The solid layer of fusible material thus acts as a mechanical support for the staples as they are initially placed in the fragile lung tissue. In addition to such initial mechanical support, however, the present invention provides for subsequent sealing of the lung tissue along and around the staple line by application of energy to the wound region to initiate fusion of the material to the underlying lung tissue. Fusion of the material effects sealing of perforations in the wound region which may be due to the initial stapling or other causes. In particular, sealing of the fusible material to the

underlying tissue over regions adjacent to all sides of the staple line will inhibit or prevent leakage past the edges of the solid layer of fusible material which is formed. Additionally, fusing of the backing layer will provide "stress relief" to permit realignment of the individual staples to reduce tearing and damage to the lung tissue as the lung expands and contracts during respiration.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic illustration of a lung having diseased tissue regions.

Figs. 2A-2E illustrate a method according to the principles of the present invention where a strip of fusible material is placed along an excision line prior to stapling and excision using a conventional stapling apparatus.

Fig. 3 illustrates a conventional stapling apparatus having a sleeve of fusible material disposed over the head and anvil.

Figs. 4A and 4B illustrate an alternative method according to the present invention for excising and sealing diseased lung tissue, where the diseased tissue is first excised and stapled and a non-solid fusible material then applied over the stapled region prior to applying energy.

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods and devices according to the present invention may be used for closing wounds in virtually any body tissue, and are particularly useful for closing wounds in the tissue of fragile body organs, such as lungs, stomach, liver, spleen, intestines, colon, and the like. The wounds may result from accidental trauma, surgical intervention, or virtually any other cause, with the methods and devices being particularly useful for the closure of surgical resections made in the lungs (lung volume reductions, bullectomies, lobectomies, segmentectomies, bronchial resections, wedge resections, pneumonectomies, pneumoreductions, etc.), in the gastrointestinal tract, (gastrectomies, intestinal/colon resection), in the liver, and in the spleen. The present

invention provides both secure mechanical closure of the wound and prevention or inhibition of fluid leakage, including both air leakage and liquid fluid leakage, such as blood and other bodily fluids. The present invention is particularly suitable  
5 for performing lung resections where the remaining portion of the lung is closed and sealed along the resection line.

The present invention relies on the use of conventional surgical fasteners for initial closing of the wound. Exemplary fasteners include suture, staples, clips,  
10 pins, hooks, and the like. The present invention is particularly useful with surgical stapling devices, such as multiple row, in-line staplers of the type available from U.S. Surgical Corp., Norwalk, Connecticut, and Ethicon, Inc.,  
Somerville, New Jersey, including both disposable and reusable  
15 devices, such as those devices intended for use in laparoscopic procedures.

The present invention particularly relies on applying a fusible material to the region on the outer tissue surface surrounding the wound, where the fusible material may  
20 penetrate at least to some extent to the inner wound surfaces that are being joined by the procedure. The fasteners used in the primary closure of the wound penetrations will usually cause perforations in the tissue surrounding the wound as the mechanical closure is effected. The presence of the fasteners  
25 in the penetrations will often impart some stress to the tissue, where the stress in turn can result in enlargement of the penetration(s). This is a particular problem with staple closures of the lung, where lung inflation during respiration can place significant stress on the lung tissue, especially at  
30 the edges of the resection line, causing the staples to enlarge the penetrations and permit significant air loss, as described previously. Stress can also concentrate at the edge of conventional pericardial patches, which in turn can tear lung tissue and cause air leakage. The fusible materials of  
35 the present invention (which upon application of energy bond and seal to the underlying tissue) can act to seal such perforations and enlarged penetrations and thus enhance the mechanical integrity of the wound closure. Moreover, solid

sheets of fusible materials may be used as a backing or reinforcement layer to help anchor staples and other fasteners during initial placement of the fasteners prior to fusing.

The fusible material may be any natural, modified  
5 natural, or synthetic substance which has the ability to be applied over the wound region in a solid or non-solid state, and thereafter to be fused to the underlying tissue surrounding the closed wound upon the application of energy from a suitable energy source. Thus, the fusible material  
10 will be able to create and/or maintain a solid, continuous film over (and sometimes penetrating into) the wound region to act both to mechanically enhance the wound closure and/or seal any perforations which may be present in the region. Such fusible materials should also be biocompatible (e.g., should  
15 be non-immunogenic and non-inflammatory), and usually (but not necessarily) will be bioabsorbable overtime (e.g., being partially or completely resorbed into the underlying tissue over a period from 1 day to 90 days. Suitable synthetic materials include organic polymer films which contain or have  
20 been modified to contain side groups which will bond (covalently or hydrostatically) or otherwise adhere to the underlying tissue. Exemplary synthetic materials suitable for use in the present invention include organic polymers such as poly(lactic acid), poly(glycolic acid), poly(hydroxybuterate),  
25 poly(phosphazine), polyester, and the like.

Generally, the use of natural biological polymers, and in particular biological proteins, is preferred. Suitable proteins include collagen, fibrin, fibrinogen, elastin, albumin, combinations thereof, and the like, and mixtures and  
30 derivatives thereof. Particularly preferred is the use of collagen and modified collagens, such as gelatin (which is a protein-containing material obtained by hydrolysis of collagen in a well known manner), as described in parent Application Serial No. 08/303,336, filed on September 9, 1994, the full  
35 disclosure of which has been previously incorporated herein by reference. The fusible material will usually be applied to the wound region as a solid layer, e.g., in the form of a film, sheet, patch, strip, mesh, or the like. Use of a mesh

allows tissue to form a coagulum within the interstices of the mesh as energy is applied, as described in Patent Application Serial No. 08/303,336, the disclosure of which has been incorporated herein by reference.

5           The solid phase forms of the fusible material may optionally be reinforced with filaments, braids, meshes, and other woven and non-woven reinforcement materials. Preferably, the reinforcement materials will be non-bioabsorbable so that they will remain even after the fusible  
10 material has been resorbed. Thus, the reinforcement materials will remain to provide support for the fasteners over extended periods of time. Preferred reinforcement materials will be in the form of polymeric braids or meshes, particularly composed of polypropylene (Marlex®), fluoronated polymers (Gore-Tex ),  
15 and the like.

          The solid phase forms of the fusible material may be formed by a variety of methods as described in copending application serial no. 08/303,336, the full disclosure of which has previously been incorporated herein by reference.  
20 Reinforcement materials can be added by various known techniques, such as impregnation, dipping, casting, co-extrusion, and the like.

          Alternatively, the fusible material may be applied to the wound region in a non-solid dispersible state, e.g., as  
25 a liquid, gel, sol, paste, spray, or combination thereof. In the preferred solid layer form, the fusible material will be cut or trimmed into a desired shape prior to application to the wound region. Application to the wound region may occur before, during, or after application of the primary fasteners.  
30 In a particularly preferred embodiment, as described below, the fusible material will be applied to the tissue as a backing layer for the staples which are used as primary fasteners. Non-solid dispersible fusible materials may be applied using syringes, brushes, sprayers, spatulas, or other  
35 methods suitable for spreading or dispersing a thin layer of material over the wound region. In all cases, after application of the fusion energy, the fusible material will be in the form of a continuous solid film or gel over the wound

region. That is, fusible materials which are originally in a solid, layer form will remain as a solid film, although the film will become bound to the underlying tissue and may alter in shape to some degree. In the case of non-solid and other discontinuous phases, the fusible material will be converted into a solid or gelatinous phase upon the application of energy. In the case of a fusible material which is applied in the form of a mesh, the application of energy will usually form a coagulum of tissue within the interstices of the mesh, resulting in a solid or gelatinous, continuous film comprising both the fusible material and the tissue coagulum after the energy has been applied.

In addition to the substances described above, the fusible material of the present invention may further include dyes, pigments, and the like, which affect the energy absorption of the material in some desired manner. For example, particular dyes may be added to enhance absorption of energy from the selected energy source. Additionally, dyes and pigments may be added simply to improve visualization of the material during use and/or permit materials having different characteristics to be distinguished from each other. Other substances and additives may be included with the fusible material for other purposes, as generally described in Parent Application Serial No. 08/303,336, filed on September 9, 1994, the full disclosure of which has previously been incorporated herein by reference.

Other substances suitable for use as a component in the fusible material include glycosaminoglycans, such as hyaluronic acid, dermatan sulfate, chondroitin sulfate, and heparin. Use of the glycosaminoglycans is desirable since such materials, which are anti-thrombotics, can reduce adhesion to adjacent tissues and organs after the final solid or gelatinous layer has been formed by the application of energy.

The solid, forms of the fusible material will typically be provided as sheets, strips, films, or patches having a thickness sufficient to provide mechanical integrity both before and after application to the wound region. For

most of the materials described above, and in particular for the collagen and gelatin materials, a thickness in the range from about 0.01 mm (0.5 mils) to 0.75 mm (30 mils), with a preferred thickness from 0.04 mm (1 mil) to 0.1 mm (4 mils) is  
5 suitable. Fusible materials having thicknesses generally greater than this range are less suitable since they have poor energy absorption characteristics and display increasing stiffness. Energy absorption and conduction within patches in the upper region of this range, from 0.1 mm to 0.75 mm, can be  
10 improved by the formation of holes partially or fully through the thickness of the material (referred to as "interlock vias" in Parent Application Serial No. 08/303,336, the full disclosure of which has previously been incorporated herein by reference). The peripheral dimensions of the continuous,  
15 solid sheets of fusible material are not critical. The sheets will typically be cut or trimmed to have a desired peripheral shape prior to use in the methods in the present invention. In a particularly preferred example, as described in more detail below, the sheets of fusible material may be formed  
20 into tubes, sleeves, or strips, which can be aligned along or over the heads and/or anvils of stapling devices, so that the materials will act as backing or reinforcement layers as the staples are applied to close the wound.

The method of the present invention will utilize  
25 energy of a type and in an amount sufficient to fuse the fusible material to underlying tissue. Suitable energy sources include electrical energy, particularly RF energy sources, heat energy, laser energy, ultrasonic energy, and the like. Preferred are the use of RF energy sources, such as  
30 those available as electrosurgical power supplies from companies such as Valleylab, Boulder, Colorado, and Birtcher Medical Systems, Irvine, California, employing conventional RF-applying probes. Particularly preferred are modified radio frequency energy sources which provide for a dispersed or  
35 distributed current flow from a hand-held probe to the tissue. One such radio frequency energy source referred to as an inert gas beam coagulator which relies on flow of an inert ionizable

gas, such as argon, for conducting current from the probe to the tissue.

Energy from the energy source will typically be manually directed to the tissue using a probe connected to an external power supply. The treating physician will manually direct the probe to apply energy over the surface of the fusible material and will visually confirm that fusion has been achieved. The probe may use conventional electrosurgical power supplies having an energy output from 2 W to 100 W, preferably from 20 W to 40 W. The fusible material will typically be exposed to the energy for a total time from about 15 seconds to 120 seconds, usually from 30 seconds to 40 seconds, for material having an area from 1 cm<sup>2</sup> to 10 cm<sup>2</sup>. The precise timing will depend on the physician's visual assessment that fusion of the material to the underlying tissue has been achieved.

Referring now to Fig. 1, a lung L includes diseased regions R1 and R2. The diseased regions comprise giant bullae which are collapsing the adjoining gas-exchanging lung tissue. The methods and devices of the present invention may be advantageously used to resect such diseased regions R1 and R2 from the lung L and to further provide secure, generally air-tight seals along the resection lines.

Referring now to Figs. 2A-2E, diseased region R1 can be removed by applying a strip of fusible material 10 along the desired resection line, as illustrated in Fig. 2A. Preferably, a second strip will be provided on the opposite side of the lung, where the two strips are aligned prior to stapling, as shown in Fig. 2B. A conventional multiple row, in-line stapling device having an axial cutting blade disposed between a pair of double staple lines is shown in Fig. 2B. The stapler is applied over the opposed pair of fusible material strips 10, and the strips stapled together to form a sandwich along the desired section line, as shown in Fig. 2C. It will be appreciated that the tissue (as well as the fusible strips 10) have been cut along line 12 after the stapling operation. A second pair of fusible strips are then placed along the remaining length of the desired resection line, and



the stapling and resection step repeated using the same stapler having a new stapling cartridge. After the resected tissue is removed, energy is applied over the fusible material strips 10 and adjacent tissue area, typically using an inert gas beam coagulator 14 as shown in Fig. 2D.

Similar patching, stapling, and resecting steps are taken to remove the second diseased region R2, as shown in Fig. 2E. The method of the present invention is particularly useful since it also allows surface defects in the lung L to be corrected using patches 16, as also shown in Fig. 2E. The patch 16 can be cut to a desired size and geometry and placed over the lung defect. After placement, the inert gas beam coagulator 14 can be used to fuse the patch 16 to the lung tissue. At the end of the procedure, the diseased regions R1 and R2 have been removed, with the resulting resection lines sealed. Additionally, any surface defects in the lung L have been patched without tissue resection. Thus, the lung has been surgically repaired with the likelihood of perforations leading to air leaks being greatly reduced.

In order to enhance the integrity of the seal provided by tissue strips 10, it will generally be desirable to overlap the ends of multiple strips which are used in-line. Additionally, the strips 10 should extend beyond the resection line by a distance of at least 3 mm, preferably at least about 10 mm. In this way, a continuous sealing layer may be formed over all regions of the tissue which are at the greatest risk of air leakage.

In a preferred aspect of the present invention, the strips of fusible material may be initially placed over the head and/or anvil of a stapling device SD, as shown in Fig. 3. Preferably, sleeves 20 of the fusible material are wrapped around each of the anvil A unstapling head H, and secured by a strip of tape 22. The sleeves may be wrapped around the anvil head immediately prior to use, or preferably may be pre-formed and made available in a sterile package, where the physician may remove the sleeves immediately prior to use and place them over the stapling head. The sleeves may be provided in long, continuous lengths which may be cut into shorter segments

having a desired length intended to fit over commercially available staplers, e.g., 50 mm, 55 mm, 65 mm, etc. The stapler may then be used to perform the method illustrated in Figs. 2A-2E, except that there is no need to manually place strips of 10 of the fusible material prior to stapling. After stapling using the stapling device SD as shown in Fig. 3, the stapling head and anvil are separated from the cut sleeves 20, and the sleeve material may be trimmed to a desired width and geometry prior to the application of energy.

Liquid, gel, and other non-solid forms of the fusible material may be applied in a variety of manners. For example, a syringe SY may be used to apply a liquid fusible material over a wound region which has previously been stapled, as shown in Fig. 4A. The material may be applied, and optionally spread using a spatula or the like, and the fusion energy then applied using any of the sources described above, such as the inert gas beam coagulator 14 described previously. After application of energy, the fusible material will be in the form of a thin, continuous film of the material to protect and seal the wound region.

The following examples are offered by way of illustration, not by way of limitation.

## EXPERIMENTAL

### Materials and Methods

#### 1. Filtered Collagen Patch Preparation

Fibrous bovine corium collagen (Kensley-Nash Semed F collagen, Kensley-Nash Corporation, Exton, PA) was dispersed in distilled water at 10% solids (w/v). Polyethylene glycol 400 MW (PEG, U.S.P. or pharmaceutical grade) was also added to 1% solids (w/v). The dispersion was heated at 70°C for 50 minutes with occasional agitation. The dispersion was then filtered through a 100 micron mesh. The filtrate was analyzed for percent solids and was adjusted to 4% solids (including PEG) by addition of distilled water. During the filtration and dilution steps, the filtrate was maintained at temperatures >35°C to prevent gelling of the filtrate. The filtrate was poured into dishes to form gels. To achieve the

desired final patch thickness, 13 ml was poured into polystyrene petri dishes (100 x 100 x 15 mm, Baxter Scientific Products, McGaw Park, IL) and allowed to gel at room temperature (20-24°C). To achieve a patch which is uniform in thickness, the poured filtrate and dish was maintained level. The poured filtrate gelled within 30 minutes, and the gel was allowed to dry at ambient conditions. Patches were dried until the moisture content reached 10-14%(w/w). Moisture levels below 10% were undesirable, since patches could become brittle. Dried films were freed from dishes and cross-linked with UV light; 254 nm at 4.4 watts/cm<sup>2</sup> for 20-40 minutes (Model UVC-515 Ultraviolet Multi-linker, Ultra-Lum, Inc., Carson, CA). Patches were sterilized by placing in heat-sealed polyester barrier pouches, or equivalent moisture barrier enclosures, and irradiating with electron beam at 2.5-3.0 megarads (Nutek Corporation, Palo Alto, CA). The final dried, cross-linked patch was 0.04-0.06 mm thick, contained 8-20% PEG (w/w), with the remainder being cross-linked annealed gelatin. The melting temperature of the fully hydrated patch (hydrated in 0.1%aq. NaCl) by differential scanning calorimetry (DSC, Thermal Analyst 2100). TA Instruments, New Castle, DE) was 34-40°C (heating rate 10°C/min). Native collagen, which has a fully helical structure, melts at 50-70°C under the same conditions.

## 2. Granular Collagen Patch Preparation

Fibrous bovine collagen was dispersed in distilled water at 3.3-3.8%(w/v), with 0.3%(w/v) PEG 400 MW, and heated as in the filtered formulation. After 50 min at 70°C, the dispersion was circulated through a homogenizer (Virtis Cyclone IQ<sup>2</sup>, fitted with 20 mm diameter rotor-stator with flow-through head, containing slotted orifices with approximately 1 mm gap, operated at 20,000 rpm; n t fluid flow through the head :150 ml/min, controlled by a pump external to the homogenizer; two complete passes through the homogenizer). Microscopic inspection of the collagen after heating and homogenization showed that all fibrous clumps were broken up. The homogenized dispersion was then poured into dishes (total

protein solids 3.3-3.8%, w/v), gelled, dried, cross-linked, and sterilized as in the filtered patch formulation. These patches were 0.07-0.10 mm thick, due to the size of the fibers which are dried into the film. They were more opaque than the  
5 filtered formulation. DSC melting temperatures were 35 to 40°C.

### 3. Gelatin Patch Formulation

Pharmaceutical grade gelatin, from bovine or porcine  
10 source (300 Bloom, Dynagel, Inc., Calumet City, IL, or Hormel Foods Corp., Austin, MN) was dissolved at 3.3 to 3.8% (w/v) in distilled water, along with 0.3% PEG 400 MW (w/v), by heating 3-5 minutes at 50-60°C with stirring. The dissolved gelatin  
15 was cast into gels, dried, cross-linked, and sterilized as in the filtered patch formulation. These patches were 0.04 to 0.06 mm thick and almost transparent; DSC melting temperatures were 33-38°C.

### 4. RF Energy Source

20 Radio frequency current was supplied by a Birtcher 6400 Argon Beam Coagulator equipped with a triple control hand piece (3:1 probe). Energy was applied at 40 W with an Argon flow of 4 liters/min.

### 25 5. Procedure

A pig (60 kg) was anesthetized, intubated, and prepared for a thoracotomy. A right thoracotomy was made through the fourth interspace, and a substantial portion of both the upper and lower lobes of the lung was exposed.

30 A 55 mm Ethicon Proximate Linear Cutter (Ethicon, Inc., Sommerville, New Jersey) stapler was used to staple several locations in the lung, including (1) the lingula of the upper lobe, (2) the apex of the lower lobe, (3) the inferior aspect of the lower lobe which provided a relatively  
35 long 10 cm stapling site, and (4) a wedged-out segment of the lung. The filtered collagen patch, the granular patch, and the gelatin patch were each used for reinforcing the staple line applied to the lung.

5 Sheets of both the filtered collagen patch and the  
gelatin patch were placed over the stapler head and anvil  
prior to use. In both cases, the patch material was wrapped  
around the stapler head or anvil and secured as a tubular  
sleeve thereover by adhesive steri strips. The staples and  
the reinforcement patches were then applied to the lung tissue  
simultaneously in a single stapling and resection operation.  
After stapling was complete, the reinforcement patches were  
cut from the stapler head and anvil, trimmed and welded to the  
underlying lung tissue using the RF argon beam coagulator.

### Results

Both the filtered collagen patch material and the  
gelatin patch material were used successfully in the staple  
line reinforcement procedures. Each of the patch materials  
readily formed a tube which was easily wrapped around the  
stapler head/anvil. It appears that each of the collagen,  
granular collagen, and gelatin welding patch materials can be  
formed as a cylindrical tube without the need to utilize  
external tapes or other closing devices. When initially  
stapled in place, prior to application of the RF energy, each  
of the reinforcement materials provided a strong buttress  
without cracking.

After fusion to the underlying tissue, no leaks were  
observed in the region surrounding the staples and/or fused  
patch material. Welding of the collagen and gelatin materials  
was particularly useful in preventing leakage at the axial  
ends of the patches. These patches further acted to prevent  
bleeding.

Although the foregoing invention has been described  
in detail for purposes of clarity of understanding, it will be  
obvious that certain modifications may be practiced within the  
scope of the appended claims.

**WHAT IS CLAIMED IS:**

1. A method for closing a wound in tissue, said method comprising:

5       applying to a region adjacent to the wound in a predetermined order (1) fasteners to close the wound and (2) a material which fuses to the tissue upon the application of energy; and

10       applying energy to the region to fuse the material to the tissue and seal perforations in the tissue.

2. A method as in claim 1, wherein the material comprises a solid or mesh layer and the layer is applied simultaneously with the fasteners as a backing.

15

3. A method as in claim 1, wherein the material is applied before the fasteners.

4. A method as in claim 3, wherein the material is a solid or mesh layer having peripheral dimensions corresponding to the wound region and wherein the layer is positioned over the wound region prior to applying the energy.

20

5. A method as in claim 3, wherein the material is in a dispersible, non-solid phase and wherein the material is distributed over the wound region prior to applying the energy.

25

6. A method as in claim 1, wherein the material is applied after the fasteners.

30

7. A method as in claim 6, wherein the material is a solid layer or mesh having peripheral dimensions corresponding to the wound region and wherein the layer is positioned over the fasten rs before applying the energy.

35

8. A method as in claim 6, where in the material is in a dispersibl , non-solid phas and wh rein the material is distributed over the fasteners after applying the fasteners.

5 9. A method as in claim 6, wherein the material is a solid rod and wherein the material is applied by engaging the rod against the wound region over the fasteners while applying energy.

10 10. A method as in claim 1, wherein the material comprises at least one of a biologic polymer and a synthetic organic polymer.

15 11. A method as in claim 10, wherein the material comprises a protein selected from the group consisting of collagen, fibrin, fibrinogen, elastin, albumin, and combinations thereof.

20 12. A method as in claim 10, wherein the material comprises a glycosaminoglycan selected from the group consisting of hyaluronic acid, dermatan sulfate, chondroitin sulfate, and heparin.

25 13. A method as in claim 10, wherein the material comprises a synthetic organic polymer selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(hydroxybuterate), poly(phosphazine), and polyester.

30 14. A method as in claim 1, wherein the applied energy is selected from the group consisting of radio frequency energy, heat energy, laser energy, and ultrasonic energy.

35 15. A method as in claim 14 wherein the energy applying step comprises directing energy from a radio frequency inert gas coagulator applicator against the wound region.

16. A method as in claim 1, wherein the material comprises gelatin and the energy is applied at a level from 1 W/cm<sup>2</sup> to 100 W/cm<sup>2</sup> for a time sufficient for the material to fuse to the tissue without substantial loss of mechanical strength.

17. A method as in claim 1, wherein the fasteners are staples and applying the fasteners comprises simultaneously placing multiple staple lines with a stapler.

18. A method as in claim 1, wherein the material is a reinforced solid, wherein the reinforcement is composed of a non-bioabsorbable material.

19. A method for lung resection, said method comprising:  
resecting lung tissue along a resection line;  
applying along the resection line in a predetermined order (1) fasteners to close the lung tissue and (2) a material which fuses to the lung tissue upon the application of energy; and  
applying energy to the region to fuse the material to the tissue and seal perforations in the tissue.

20. A method as in claim 19, wherein the tissue resecting step and the fastener applying step are performed simultaneously with an in-line stapler having a cutting blade disposed adjacent to a multiple staple line.

21. A method as in claim 20, wherein the material comprises a solid layer disposed over the staple line and the layer is applied simultaneously with the staples as a backing.

22. A method as in claim 19, wherein the material is applied before the fasteners.



23. A method as in claim 22, wherein the material is a solid layer having peripheral dimensions corresponding to the resection line and wherein the layer is positioned over the resection line prior to applying the energy.

5

24. A method as in claim 22, wherein the material is in a dispersible, non-solid phase and wherein the material is distributed over the resection line prior to applying the energy.

10

25. A method as in claim 19, wherein the material is applied after the fasteners.

26. A method as in claim 25, wherein the material is a solid or mesh layer having peripheral dimensions sufficient to cover the resection line and adjacent tissue, wherein the layer is positioned over the resection line before applying the energy.

20

27. A method as in claim 25, wherein the material is in a dispersible, non-solid phase and wherein the material is distributed over the resection line after applying the energy.

25

28. A method as in claim 25, wherein the material is a solid rod and wherein the material is applied by engaging the rod over the resection line while applying energy.

30

29. A method as in claim 19, wherein the material comprises at least one of a biologic polymer and a synthetic organic polymer.

35

30. A method as in claim 29, wherein the material comprises a protein selected from the group consisting of collagen, fibrin, fibrinogen, elastin, albumin, and combinations thereof.

31. A method as in claim 29, wherein the material comprises a glycosaminoglycan selected from the group consisting of hyaluronic acid, dermatan sulfate, chondroitin sulfate and heparin.

32. A method as in claim 29, wherein the material comprises a synthetic organic polymer selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(hydroxybuterate), poly(phosphazine), and polyester.

33. A method as in claim 19, wherein the applied energy is selected from the group consisting of radio frequency energy, heat energy, laser energy, and ultrasonic energy.

34. A method as in claim 33, wherein the energy applying step comprises directing energy from a radio frequency inert gas coagulator applicator against the material covering the wound region.

35. A method as in claim 19, wherein the material comprises gelatin and the energy is applied at a level from 1 W/ to 100 W/ for a time sufficient for the material to fuse to the tissue without substantial loss of mechanical strength.

36. A method as in claim 19, wherein the material is a reinforced solid, wherein the reinforcement is composed of a non-bioabsorbable material.

37. Apparatus for closing a wound in tissue, said apparatus comprising;

a stapler assembly including a staple head and an anvil; and

a strip of material aligned along at least one of the stapler head and the anvil, wherein the material is fusible to tissue upon the application of energy.

38. Apparatus as in claim 37, wherein the strip is tubular and disposed over the stapler head or anvil.

5 39. Apparatus as in claim 37, wherein the material is fusible upon the application of energy from a source selected from the group consisting of radio frequency energy, heat energy, laser energy, and ultrasonic energy.

10 40. Apparatus as in claim 37, wherein the material comprises at least one of a biologic polymer and a synthetic organic polymer.

15 41. Apparatus as in claim 37 wherein the material comprises a protein selected from the group consisting of collagen, fibrin, fibrinogen, elastin, albumin, and combination thereof.

20 42. Apparatus as in claim 37, wherein the material comprises a glycosaminoglycans.

25 43. Apparatus as in claim 37, wherein the material comprises a synthetic organic polymer selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(hydroxybuterate), poly(phosphazine), and polyester.

44. Apparatus as in claim 37, wherein the material comprises a gelatin.

30 45. A tissue sealing sleeve for placement over a stapler head or anvil of a stapler assembly, said sleeve comprising a preformed tube composed of a material which fuses to tissue upon the application of energy.

35 46. A tissue sealing sleeve as in claim 45, wherein the material is fusible upon the application of energy from a source selected from the group consisting of radio frequency energy, heat energy, laser energy, and ultrasonic energy.


47. A tissue sealing sleeve as in claim 45, wher in the material comprises at least one of a biologic polymer and a synthetic organic polymer.

5           48. A tissue sealing sleeve as in claim 45, wherein the material comprises a protein selected from the group consisting of collagen, fibrin, fibrinogen, elastin, albumin, mesh and combinations thereof.


10           49. A tissue sealing sleeve as in claim 45, wherein the material comprises a synthetic organic polymer select d from the group consisting of poly(lactic acid), poly(glycolic acid), poly(hydroxybuterate), poly(phosphazine), and polyester.

15           50. A tissue sealing sleeve as in claim 45, wherein the material comprises a gelatin.

20           51. A tissue sealing sleeve as in claim 45, wherein the sleeve is reinforced with a non-bioabsorbable material.



**FIG. 1.**



**FIG. 2A.**




FIG. 2B.




FIG. 2C.




FIG. 2D.

RECTIFIED SHEET (RULE 91)




FIG. 2E.






FIG. 3.

4/4



**FIG. 4A.**



**FIG. 4B.**



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/11332

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61B 17/00

US CL : 606/7, 8, 10, 12, 17, 213, 214; 128/898

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 606/7, 8, 10, 12, 17, 213, 214; 128/898

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,854,320 (DEW ET AL.) 08 August 1989. See entire document.	1-51
Y	US, A, 5,071,417 (SINOFSKY) 10 December 1991. See entire document.	1-51
Y	SPIE, Laser Surgery: Advanced Characterization, Therapeutics and Systems II, Volume 1200, issued 1990, Oz et al., "Preliminary report: laser welding and fibrinogen soldering are superior to sutured cholecystostomy closure in a canine model", pages 55-59. See entire document.	1-51



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 OCTOBER 1995

Date of mailing of the international search report

20 NOV 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RAJ BAWA, Ph.D.

Telephone No. (703) 308-2351

THIS PAGE BLANK (USPTO)